Retinal Imaging in Neurodegenerative Disease

Launched by DUKE UNIVERSITY · Jul 26, 2017

Keywords

ClinConnect Summary

This clinical trial, titled "Retinal Imaging in Neurodegenerative Disease," is focused on using advanced imaging techniques to better understand eye health in people with various brain disorders, including Alzheimer's Disease, Parkinson's Disease, and Mild Cognitive Impairment, among others. The goal is to find new ways to measure changes in the eye that may help doctors understand how these diseases affect patients. Researchers will use non-invasive methods like optical coherence tomography (OCT) and ultra-widefield fundus photography, which are safe and painless ways to take detailed pictures of the retina, the light-sensitive layer at the back of the eye.

Adults aged 65 to 74 with or without neurodegenerative diseases may be eligible to participate in this study. Participants will undergo imaging tests that don't require any surgery, making it a low-risk option for individuals. It’s important to note that anyone who has had significant eye surgery, other than cataract surgery, may not be able to join. If you're selected, you can expect to help researchers gather valuable information that could lead to better understanding and treatment of these conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
• • Adults without neurodegenerative disease
• Exclusion Criteria:
• • Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.
• • Eyes that have had intraocular surgery, other than cataract surgery.
• • If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.